These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 3648093)

  • 1. Specific inhibitor of complement (C5)-derived chemotactic activity in systemic lupus erythematosus related antigenically to the Bb fragment of human factor B.
    Perez HD; Hooper C; Volanakis J; Ueda A
    J Immunol; 1987 Jul; 139(2):484-9. PubMed ID: 3648093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphonuclear leukocyte chemotaxis in systemic lupus erythematosus.
    Perez HD; Goldstein IM
    J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():53-8. PubMed ID: 3612652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.
    Perez HD; Lipton M; Goldstein IM
    J Clin Invest; 1978 Jul; 62(1):29-38. PubMed ID: 659635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of the chemotactic activity of human C5a des Arg by an anionic polypeptide ("cochemotaxin") in normal serum and plasma.
    Perez HD; Goldstein IM; Webster RO; Henson PM
    J Immunol; 1981 Feb; 126(2):800-4. PubMed ID: 7451994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attachment of human C5a des Arg to its cochemotaxin is required for maximum expression of chemotactic activity.
    Perez HD; Chenoweth DE; Goldstein IM
    J Clin Invest; 1986 Dec; 78(6):1589-95. PubMed ID: 3782473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human C5a and C5a des Arg exhibit chemotactic activity for fibroblasts.
    Senior RM; Griffin GL; Perez HD; Webster RO
    J Immunol; 1988 Nov; 141(10):3570-4. PubMed ID: 3183381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Group B streptococci inhibit the chemotactic activity of the fifth component of complement.
    Hill HR; Bohnsack JF; Morris EZ; Augustine NH; Parker CJ; Cleary PP; Wu JT
    J Immunol; 1988 Nov; 141(10):3551-6. PubMed ID: 3053900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of chemotactic factor inactivator in modulating alveolar macrophage-derived neutrophil chemotactic activity.
    Robbins RA; Justice JM; Rasmussen JK; Russ WD; Thomas KR; Rennard SI
    J Lab Clin Med; 1987 Feb; 109(2):164-70. PubMed ID: 3805869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotactic peptides modulate adherence of human polymorphonuclear leukocytes to monolayers of cultured endothelial cells.
    Charo IF; Yuen C; Perez HD; Goldstein IM
    J Immunol; 1986 May; 136(9):3412-9. PubMed ID: 3514759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg.
    Marder SR; Chenoweth DE; Goldstein IM; Perez HD
    J Immunol; 1985 May; 134(5):3325-31. PubMed ID: 3884709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the C5a des Arg cochemotaxin. Homology with vitamin D-binding protein (group-specific component globulin).
    Perez HD; Kelly E; Chenoweth D; Elfman F
    J Clin Invest; 1988 Jul; 82(1):360-3. PubMed ID: 3392212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotactic factor inactivator interaction with Gc-globulin (vitamin D-binding protein). A mechanism of modulating the chemotactic activity of C5a.
    Robbins RA; Hamel FG
    J Immunol; 1990 Mar; 144(6):2371-6. PubMed ID: 2313096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenic identification of chemotactic factor inactivator in normal human serum and bronchoalveolar lavage fluid.
    Robbins RA; Rasmussen JK; Clayton ME; Gossman GL; Kendall TJ; Rennard SI
    J Lab Clin Med; 1987 Sep; 110(3):292-9. PubMed ID: 3611952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human monocyte adherence: a primary effect of chemotactic factors on the monocyte to stimulate adherence to human endothelium.
    Doherty DE; Haslett C; Tonnesen MG; Henson PM
    J Immunol; 1987 Mar; 138(6):1762-71. PubMed ID: 3819394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gc-globulin (vitamin D-binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg.
    Kew RR; Webster RO
    J Clin Invest; 1988 Jul; 82(1):364-9. PubMed ID: 3392213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement (C5)-derived chemotactic activity in serum from patients with pancreatitis.
    Perez HD; Horn JK; Ong R; Goldstein IM
    J Lab Clin Med; 1983 Jan; 101(1):123-9. PubMed ID: 6848611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of C5a antagonist by synovial and peritoneal tissue fibroblasts.
    Matzner Y; Gavison R; Shlomai Z; Ben-Bassat H; Liebergal M; Robinson DR; Babior BM
    J Cell Physiol; 1986 Nov; 129(2):215-20. PubMed ID: 3771654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of endotoxin-induced C5-derived chemotactic activity in aqueous humor.
    Rosenbaum JT; Wong K; Perez HD; Raymond W; Howes EL
    Invest Ophthalmol Vis Sci; 1984 Oct; 25(10):1184-91. PubMed ID: 6384121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of induction of IL-1 production in human monocytes by complement fragments.
    Arend WP; Massoni RJ; Niemann MA; Giclas PC
    J Immunol; 1989 Jan; 142(1):173-8. PubMed ID: 2783323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin.
    Takematsu H; Tagami H
    Arch Dermatol; 1993 Jan; 129(1):74-80. PubMed ID: 8420495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.